CTGov Compliance My Organizations

Compliance Rate

Compliance Rate 0%

Compliant submissions 0

Incompliant submissions 0

Total trials 0

My Organizations' Clinical Trials

Showing 50 of 111 entries

View as:

BAX 326 Surgery Study in Hemophilia B Patients

Phase: N/A Priority: Normal

NCT ID: NCT01507896 Org: User:

Start: 12/19/11 End: 05/15/14 Due: 05/15/15

A Phase 1/2 Study of SHP648, an Adeno-Associated Viral Vector for Gene Transfer in Hemophilia B Subjects

Phase: N/A Priority: Normal

NCT ID: NCT04394286 Org: User:

Start: 05/13/20 End: 05/03/21 Due: 05/03/22

Pharmacokinetic Study of ARALAST (Human Alpha1- PI)

Phase: N/A Priority: Normal

NCT ID: NCT00242385 Org: User:

Start: 12/20/05 End: 06/05/06 Due: 06/05/07

BAX 826 Dose-Escalation Safety Study

Phase: N/A Priority: Normal

NCT ID: NCT02716194 Org: User:

Start: 03/03/16 End: 01/17/17 Due: 01/17/18

Safety and Efficacy Study of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients Undergoing Surgery

Phase: N/A Priority: Normal

NCT ID: NCT00157105 Org: User:

Start: 02/12/01 End: 08/03/04 Due: 08/03/05

BAX 855 PK-guided Dosing

Phase: N/A Priority: Normal

NCT ID: NCT02585960 Org: User:

Start: 11/23/15 End: 08/05/18 Due: 08/05/19

Tolerability and Safety of Immune Globulin Subcutaneous Solution (IGSC) and rHuPH20 in PID

Phase: N/A Priority: Normal

NCT ID: NCT01175213 Org: User:

Start: 07/28/10 End: 08/06/13 Due: 08/06/14

Gammagard Liquid and rHuPH20 in PID

Phase: N/A Priority: Normal

NCT ID: NCT00814320 Org: User:

Start: 12/18/08 End: 11/11/10 Due: 11/11/11

Evaluation of Different Dose Regimens of Aes-103 Given for 28 Days to Subjects With Stable Sickle Cell Disease

Phase: N/A Priority: Normal

NCT ID: NCT01987908 Org: User:

Start: 12/03/13 End: 03/16/15 Due: 03/16/16

Phase 1 Dosing Study of BAX 513 in Healthy Volunteers

Phase: N/A Priority: Normal

NCT ID: NCT01063101 Org: User:

Start: 01/29/10 End: 08/01/10 Due: 08/01/11

BAX 855 Continuation

Phase: N/A Priority: Normal

NCT ID: NCT01945593 Org: User:

Start: 10/15/13 End: 03/02/18 Due: 03/02/19

Prospective Psychometric Evaluation Study of a Patient-reported Outcomes (PRO) Instrument for Congenital Thrombotic Thrombocytopenic Purpura (cTTP, Upshaw-Schulman Syndrome [USS], Hereditary Thrombotic Thrombocytopenic Purpura [hTTP]

Phase: N/A Priority: Normal

NCT ID: NCT03519672 Org: User:

Start: 07/12/18 End: 04/08/19 Due: 04/08/20

Efficacy and Safety Study of Protein C Concentrate in Subjects With Severe Congenital Protein C Deficiency

Phase: N/A Priority: Normal

NCT ID: NCT00157118 Org: User:

Start: 08/22/03 End: 03/17/05 Due: 03/17/06

IMMUNINE Pre-Treatment Study

Phase: N/A Priority: Normal

NCT ID: NCT01128881 Org: User:

Start: 05/31/10 End: 08/28/12 Due: 08/28/13

A Phase II Non-Controlled, Open-Label, Efficacy, Safety, Pharmacokinetic, and Pharmacodynamic Study of Pacritinib in Myelofibrosis

Phase: N/A Priority: Normal

NCT ID: NCT02584777 Org: User:

Start: 11/30/15 End: 08/31/20 Due: 08/31/21

Pharmacokinetic Study of ADVATE Reconstituted in 2 mL Sterile Water for Injection

Phase: N/A Priority: Normal

NCT ID: NCT00952822 Org: User:

Start: 08/08/08 End: 10/23/09 Due: 10/23/10

Phase 3 IGIV, 10% in Alzheimer´s Disease

Phase: N/A Priority: Normal

NCT ID: NCT01524887 Org: User:

Start: 01/23/12 End: 07/16/13 Due: 07/16/14

Long-Term Study of IGIV, 10% in Alzheimer´s Disease

Phase: N/A Priority: Normal

NCT ID: NCT01736579 Org: User:

Start: 11/29/12 End: 06/04/13 Due: 06/04/14

Non-Interventional Study to Capture the Patient Experience on Gene Therapy for Hemophilia Within the AskBio009-101 Study Through Patient and Investigator Interviews

Phase: N/A Priority: Normal

NCT ID: NCT03054389 Org: User:

Start: 03/31/17 End: 06/06/17 Due: 06/06/18

Pharmacokinetic Study of ADVATE 3000 IU in Previously Treated Patients With Severe Hemophilia A

Phase: N/A Priority: Normal

NCT ID: NCT00916032 Org: User:

Start: 06/29/09 End: 04/01/10 Due: 04/01/11

BAX 855 Dose-Escalation Safety Study

Phase: N/A Priority: Normal

NCT ID: NCT01599819 Org: User:

Start: 09/30/11 End: 07/27/12 Due: 07/27/13

Study to Determine the Dose of Recombinant Human Hyaluronidase Needed to Infuse a Full Dose of IGIV Subcutaneously

Phase: N/A Priority: Normal

NCT ID: NCT00782106 Org: User:

Start: 12/04/06 End: 11/01/07 Due: 11/01/08

Phase 1 Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Solid Tumors

Phase: N/A Priority: Normal

NCT ID: NCT01765790 Org: User:

Start: 06/14/12 End: 07/28/16 Due: 07/28/17

Efficacy and Safety of SM101 in the Treatment of IgA Nephropathy

Phase: N/A Priority: Normal

NCT ID: NCT02605525 Org: User:

Start: 12/31/15 End: 11/30/16 Due: 11/30/17

ADVATE 2 mL Post-Authorization Safety Surveillance (PASS)

Phase: N/A Priority: Normal

NCT ID: NCT02093741 Org: User:

Start: 09/20/13 End: 01/20/16 Due: 01/20/17

Title	NCT ID	Organization	User	Status	Start Date	End Date	Reporting Due Date	Last Checked	User Role	Org Created
BAX 326 Surgery Study in Hemophilia B Patients	NCT01507896	Baxalta now part of Shire	user2@example.com	None	2011-12-19	2014-05-15	2015-05-15	-	-	2025-07-14
A Phase 1/2 Study of SHP648, an Adeno-Associated Viral Vector for Gene Transfer in Hemophilia B Subjects	NCT04394286	Baxalta now part of Shire	user2@example.com	None	2020-05-13	2021-05-03	2022-05-03	-	-	2025-07-14
Pharmacokinetic Study of ARALAST (Human Alpha1- PI)	NCT00242385	Baxalta now part of Shire	user2@example.com	None	2005-12-20	2006-06-05	2007-06-05	-	-	2025-07-14
BAX 826 Dose-Escalation Safety Study	NCT02716194	Baxalta now part of Shire	user2@example.com	None	2016-03-03	2017-01-17	2018-01-17	-	-	2025-07-14
Safety and Efficacy Study of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients Undergoing Surgery	NCT00157105	Baxalta now part of Shire	user2@example.com	None	2001-02-12	2004-08-03	2005-08-03	-	-	2025-07-14
BAX 855 PK-guided Dosing	NCT02585960	Baxalta now part of Shire	user2@example.com	None	2015-11-23	2018-08-05	2019-08-05	-	-	2025-07-14
Tolerability and Safety of Immune Globulin Subcutaneous Solution (IGSC) and rHuPH20 in PID	NCT01175213	Baxalta now part of Shire	user2@example.com	None	2010-07-28	2013-08-06	2014-08-06	-	-	2025-07-14
Gammagard Liquid and rHuPH20 in PID	NCT00814320	Baxalta now part of Shire	user2@example.com	None	2008-12-18	2010-11-11	2011-11-11	-	-	2025-07-14
Evaluation of Different Dose Regimens of Aes-103 Given for 28 Days to Subjects With Stable Sickle Cell Disease	NCT01987908	Baxalta now part of Shire	user2@example.com	None	2013-12-03	2015-03-16	2016-03-16	-	-	2025-07-14
Phase 1 Dosing Study of BAX 513 in Healthy Volunteers	NCT01063101	Baxalta now part of Shire	user2@example.com	None	2010-01-29	2010-08-01	2011-08-01	-	-	2025-07-14
BAX 855 Continuation	NCT01945593	Baxalta now part of Shire	user2@example.com	None	2013-10-15	2018-03-02	2019-03-02	-	-	2025-07-14
Prospective Psychometric Evaluation Study of a Patient-reported Outcomes (PRO) Instrument for Congenital Thrombotic Thrombocytopenic Purpura (cTTP, Upshaw-Schulman Syndrome [USS], Hereditary Thrombotic Thrombocytopenic Purpura [hTTP]	NCT03519672	Baxalta now part of Shire	user2@example.com	None	2018-07-12	2019-04-08	2020-04-08	-	-	2025-07-14
Efficacy and Safety Study of Protein C Concentrate in Subjects With Severe Congenital Protein C Deficiency	NCT00157118	Baxalta now part of Shire	user2@example.com	None	2003-08-22	2005-03-17	2006-03-17	-	-	2025-07-14
IMMUNINE Pre-Treatment Study	NCT01128881	Baxalta now part of Shire	user2@example.com	None	2010-05-31	2012-08-28	2013-08-28	-	-	2025-07-14
A Phase II Non-Controlled, Open-Label, Efficacy, Safety, Pharmacokinetic, and Pharmacodynamic Study of Pacritinib in Myelofibrosis	NCT02584777	Baxalta now part of Shire	user2@example.com	None	2015-11-30	2020-08-31	2021-08-31	-	-	2025-07-14
Pharmacokinetic Study of ADVATE Reconstituted in 2 mL Sterile Water for Injection	NCT00952822	Baxalta now part of Shire	user2@example.com	None	2008-08-08	2009-10-23	2010-10-23	-	-	2025-07-14
Phase 3 IGIV, 10% in Alzheimer´s Disease	NCT01524887	Baxalta now part of Shire	user2@example.com	None	2012-01-23	2013-07-16	2014-07-16	-	-	2025-07-14
Long-Term Study of IGIV, 10% in Alzheimer´s Disease	NCT01736579	Baxalta now part of Shire	user2@example.com	None	2012-11-29	2013-06-04	2014-06-04	-	-	2025-07-14
Non-Interventional Study to Capture the Patient Experience on Gene Therapy for Hemophilia Within the AskBio009-101 Study Through Patient and Investigator Interviews	NCT03054389	Baxalta now part of Shire	user2@example.com	None	2017-03-31	2017-06-06	2018-06-06	-	-	2025-07-14
Pharmacokinetic Study of ADVATE 3000 IU in Previously Treated Patients With Severe Hemophilia A	NCT00916032	Baxalta now part of Shire	user2@example.com	None	2009-06-29	2010-04-01	2011-04-01	-	-	2025-07-14
BAX 855 Dose-Escalation Safety Study	NCT01599819	Baxalta now part of Shire	user2@example.com	None	2011-09-30	2012-07-27	2013-07-27	-	-	2025-07-14
Study to Determine the Dose of Recombinant Human Hyaluronidase Needed to Infuse a Full Dose of IGIV Subcutaneously	NCT00782106	Baxalta now part of Shire	user2@example.com	None	2006-12-04	2007-11-01	2008-11-01	-	-	2025-07-14
Phase 1 Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Solid Tumors	NCT01765790	Baxalta now part of Shire	user2@example.com	None	2012-06-14	2016-07-28	2017-07-28	-	-	2025-07-14
Efficacy and Safety of SM101 in the Treatment of IgA Nephropathy	NCT02605525	Baxalta now part of Shire	user2@example.com	None	2015-12-31	2016-11-30	2017-11-30	-	-	2025-07-14
ADVATE 2 mL Post-Authorization Safety Surveillance (PASS)	NCT02093741	Baxalta now part of Shire	user2@example.com	None	2013-09-20	2016-01-20	2017-01-20	-	-	2025-07-14

Compliance Rate

My Organizations' Clinical Trials

Appearance